Tech Company Financing Transactions
Axial Biotherapeutics Funding Round
On 12/1/2016, Axial Biotherapeutics secured $19 million in Series A funding from Domain Associates, Longwood Fund and Heritage Capital.
Transaction Overview
Company Name
Announced On
12/1/2016
Transaction Type
Venture Equity
Amount
$19,000,000
Round
Series A
Investors
Domain Associates (Lead Investor) (Michelle Dipp)
Longwood Fund (Lead Investor) (David Donabedian)
Proceeds Purpose
Proceeds purposes were not disclosed.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
400 Tradecenter Dr. 6990
Woburn, MA 01801
USA
Woburn, MA 01801
USA
Phone
Website
Email Address
Overview
Axial Biotherapeutics is a biopharmaceutical company harnessing the link between the human gut microbiome and Central Nervous System to develop a new class of therapeutics to improve the quality of life for people with CNS diseases and disorders.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Stewart Campbell
Chief Financial Officer
Jeffrey Young
Vice President
Federico Bolognani
VP - Finance
Maura Moroni
VP - Operations
Chris Meyer
Browse more venture capital transactions:
Prev: 12/1/2016: Civis Analytics venture capital transaction
Next: 12/1/2016: Sudden Coffee venture capital transaction
Share this article
News on VC Transactions
We do our best to report on all VC transactions involving tech companies. VC investment data records on this site are sourced from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs